MeSH D015458 - t-cell leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | Nelarabine | Nelarabine | 2024-08-01 | |||
| Amneal Pharmaceuticals | Nelarabine | Nelarabine | 2023-04-04 | |||
| Dr Reddys Laboratories | Nelarabine | Nelarabine | 2022-12-23 | |||
| Gland Pharma | Nelarabine | Nelarabine | 2024-01-03 | |||
| Meitheal Pharmaceuticals | Nelarabine | Nelarabine | 2023-01-10 | |||
| MSN Laboratories | Nelarabine | Nelarabine | 2024-09-13 | |||
| Nexus Biopharma | Nelarabine | Nelarabine | 2023-06-02 | |||
| Sandoz | Nelarabine | Atriance | 2007-08-22 | |||
| Nelarabine | Arranon | 2005-10-28 | ||||
| XGen Pharmaceuticals | Nelarabine | Nelarabine | 2024-09-05 | |||
| Zydus Therapeutics | Nelarabine | Nelarabine | 2021-11-17 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
38%12/32
Phase 2
54%13/24
Phase 3
6%1/17
Approved: 1Overall Success rate: 1%
All Clinical Trials
No data
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use